$32.28
0.03% yesterday
Nasdaq, Sep 27, 10:01 pm CET
ISIN
US85205L1070
Symbol
SWTX
Sector
Industry

SpringWorks Therapeutics Inc Target price 2024 - Analyst rating & recommendation

SpringWorks Therapeutics Inc Classifications & Recommendation:

Buy
100%

SpringWorks Therapeutics Inc Price Target

Target Price $68.13
Price $32.28
Potential
Number of Estimates 8
8 Analysts have issued a price target SpringWorks Therapeutics Inc 2025 . The average SpringWorks Therapeutics Inc target price is $68.13. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 8 Analysts recommend SpringWorks Therapeutics Inc to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the SpringWorks Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the SpringWorks Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 5.45 195.17
3,481.05%
EBITDA Margin -6,263.30% -142.10%
97.73%
Net Margin -7,017.23% -126.27%
98.20%

7 Analysts have issued a sales forecast SpringWorks Therapeutics Inc 2024 . The average SpringWorks Therapeutics Inc sales estimate is

$195m
Unlock
. This is
126.44% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$211m 144.39%
Unlock
, the lowest is
$174m 102.41%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $5.5m
2024
$195m 3,481.05%
Unlock
2025
$382m 95.79%
Unlock
2026
$617m 61.50%
Unlock
2027
$1.2b 88.32%
Unlock

3 Analysts have issued an SpringWorks Therapeutics Inc EBITDA forecast 2024. The average SpringWorks Therapeutics Inc EBITDA estimate is

$-277m
Unlock
. This is
12.86% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-244m 23.34%
Unlock
, the lowest is
$-319m 0.07%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-341m 22.44%
2024
$-277m 18.75%
Unlock
2025
$-170m 38.86%
Unlock
2026
$-135m 20.43%
Unlock

EBITDA Margin

2023 -6,263.30%
2024
-142.10% 97.73%
Unlock
2025
-44.37% 68.78%
Unlock
2026
-21.86% 50.73%
Unlock

7 SpringWorks Therapeutics Inc Analysts have issued a net profit forecast 2024. The average SpringWorks Therapeutics Inc net profit estimate is

$-246m
Unlock
. This is
22.46% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-210m 33.88%
Unlock
, the lowest is
$-321m 0.93%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-382m 1.15%
2024
$-246m 35.56%
Unlock
2025
$-135m 45.11%
Unlock
2026
$-32.9m 75.66%
Unlock
2027
$124m 476.70%
Unlock

Net Margin

2023 -7,017.23%
2024
-126.27% 98.20%
Unlock
2025
-35.40% 71.96%
Unlock
2026
-5.33% 84.94%
Unlock
2027
10.67% 300.19%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -5.15 -3.32
1.15% 35.53%
P/E negative
EV/Sales 10.35

7 Analysts have issued a SpringWorks Therapeutics Inc forecast for earnings per share. The average SpringWorks Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-3.32
Unlock
. This is
22.43% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.83 33.88%
Unlock
, the lowest is
$-4.32 0.93%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-5.15 1.15%
2024
$-3.32 35.53%
Unlock
2025
$-1.82 45.18%
Unlock
2026
$-0.44 75.82%
Unlock
2027
$1.67 479.55%
Unlock

P/E ratio

Current -7.55 58.61%
2024
-9.73 28.87%
Unlock
2025
-17.72 82.12%
Unlock
2026
-72.81 310.89%
Unlock
2027
19.33 126.55%
Unlock

Based on analysts' sales estimates for 2024, the SpringWorks Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

10.35
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
12.28
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 23.44
2024
10.35 55.83%
Unlock
2025
5.29 48.93%
Unlock
2026
3.27 38.08%
Unlock
2027
1.74 46.90%
Unlock

P/S ratio

Current
2024
12.28 55.84%
Unlock
2025
6.27 48.93%
Unlock
2026
3.88 38.08%
Unlock
2027
2.06 46.90%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today